Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver

NCT03619837 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03619837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
Lead sponsor
University of California, San Francisco
Phase
Phase 4
Overall status
Completed
Start date
July 15, 2018
Completion date
August 13, 2020
Enrollment
122 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, transplantation disease transmission